NEW YORK (GenomeWeb) – Clinical trials in oncology may benefit from relying on personalized combination therapies rather than matching patients to monotherapies, according to a new analysis from the Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) team.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.